Figures & data
Table 1 Baseline Characteristics of the Patients with HCC Who Received TACE and HAIC Therapy Before and After PSM
Figure 1 Enrollment pathway of patients with high-risk hepatocellular carcinoma(hHCC) who underwent HAIC and TACE therapy. *High risk: patients with Vp4 portal vein tumor thrombosis (PVTT), bile duct invasion, or a tumor infiltration volume of more than 50%.
![Figure 1 Enrollment pathway of patients with high-risk hepatocellular carcinoma(hHCC) who underwent HAIC and TACE therapy. *High risk: patients with Vp4 portal vein tumor thrombosis (PVTT), bile duct invasion, or a tumor infiltration volume of more than 50%.](/cms/asset/8d1537f0-de68-402f-81e4-d08e39c3b3ae/djhc_a_12301599_f0001_c.jpg)
Figure 2 Comparison of survival between patients who received HAIC and TACE. Kaplan–Meier curves for the progression-free survival(PFS) and overall survival(OS) before and after propensity score matching (PSM).PFS before PSM (a), OS before PSM (b); PFS after PSM (c), OS after PSM (d).
![Figure 2 Comparison of survival between patients who received HAIC and TACE. Kaplan–Meier curves for the progression-free survival(PFS) and overall survival(OS) before and after propensity score matching (PSM).PFS before PSM (a), OS before PSM (b); PFS after PSM (c), OS after PSM (d).](/cms/asset/4f6ef5e4-801f-4826-80b4-659a473bc2ba/djhc_a_12301599_f0002_c.jpg)
Table 2 Summary of Best Overall Response Before and After PSM
Table 3 Univariate and Multivariate Analysis of Risk Factors for Progression-Free Survival and Overall Survival After Matching
Figure 3 Forest plot showing the subgroup analysis of progression-free survival (a) and overall survival (b).
![Figure 3 Forest plot showing the subgroup analysis of progression-free survival (a) and overall survival (b).](/cms/asset/7b81fb91-9181-45a4-8bef-1eb4f3b770b5/djhc_a_12301599_f0003_c.jpg)
Table 4 Treatment-Related Adverse Events